INTRODUCTION

Chronic obstructive pulmonary disease (COPD)
is characterized by persistent airflow obstruction and is a major contributor to global morbidity and mortality [1] . Bronchodilators [e.g., long-acting beta 2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)] are central to the pharmacological management of symptomatic COPD [1] . However, use of bronchodilator monotherapy is frequently associated with ongoing dyspnea [2] . Combining two bronchodilators with different mechanisms of action could increase bronchodilation with equivalent or fewer side effects compared with increasing the dose of a single agent [1] . A common stepwise treatment approach to attain dual bronchodilation is to co-administer LAMA and inhaled corticosteroid (ICS)/LABA as triple therapy [3, 4] . Retrospective large UK database studies have suggested that this triple regimen is associated with reductions in exacerbations and all-cause mortality compared with ICS/LABA alone [3, 5] . However, the efficacy and safety of adding a LAMA to ICS/LABA has been tested in a limited number of randomized, double-blind clinical trials, and therefore further investigation is warranted [6, 7] .
Umeclidinium bromide 62.5 lg (UMEC, GSK573719; GSK, London, UK) is a once-daily LAMA indicated for the maintenance treatment of patients with symptomatic COPD [8, 9] . Four studies have examined the efficacy of UMEC added to once-or twice-daily ICS/LABA therapy, all of which demonstrated that UMEC (62.5 or 125 lg) ? ICS/LABA improved trough forced expiratory volume in 1 s (FEV 1 ) compared with placebo (PBO) ? ICS/LABA [10, 11] . These individual studies were not powered to detect treatment differences on patient-reported outcomes (PROs) and individual studies failed to demonstrate consistent benefits on PROs [10, 11] . Consequently, an integrated analysis was designed, pooling the data from all four studies to examine PROs in greater detail and to also facilitate subgroup analysis.
Guidelines suggest patients with COPD can be categorized into one of four Global initiative for chronic Obstructive Lung Disease (GOLD) patient groups (A-D) and recommend that therapy should be prescribed accordingly [1] . As patients in GOLD groups A and C present with a lower symptom burden than those in groups B and D [1] , groups A and C were excluded from all four clinical trials examining triple therapy included in this post hoc analysis [10, 11] . Specifically, patients in GOLD group B and D had moderate-to-severe dyspnea [1] .
Additionally, GOLD B included patients with moderate airflow limitation (FEV 1 C50% predicted) and a low future risk of exacerbations, whereas GOLD D included patients with severe-to-very-severe airflow limitation (FEV 1 \50% predicted) and a high future risk of exacerbations [1] .
When prescribing a LAMA added to ICS/ LABA, physicians choose the LAMA and ICS/ LABA combination they consider most likely to benefit their patients [1] Further details of the trial designs have been previously published [10, 11] .
Post Hoc Analysis
The primary endpoint for the four studies and the first endpoint examined in this post hoc analysis was trough FEV 1 
RESULTS
Baseline Characteristics
A total of 3191 patients were recruited to these four studies, with data from 2458 patients in the Table 2 ).
All patients enrolled n=3191
Randomized n=2464
Intent-to-treat n=2458 CI 118, 175; GOLD D: 119 mL, 95% CI 98, 141; both P\0.001; Table 3 ). The 24-h serial FEV 1 treatment differences were greater at Days
84-85 versus Days 1-2 in both GOLD
subgroups and appeared to be greater in the GOLD B population (Fig. 3a, Table 3 ). The magnitude of these treatment differences appeared similar ( Table 3 ). The sustained 24-h efficacy versus PBO ? ICS/LABA, as assessed via serial FEV 1 , appeared similar in patients receiving either ICS/LABA treatment in combination with UMEC 62.5 lg (Fig. 3c, d ).
Patient-Reported Outcomes
Improvements in rescue-medication use (mean puffs/day and % rescue-free days; weeks 1-12), however, this was not statistically significant (HR 0.58; 95% CI 0.33, 1.02; P = 0.058; Fig. 4b ).
Safety
The overall incidence of AEs was similar across treatment groups, with nasopharyngitis, headache and back pain the most commonly reported AEs ( A total of eight fatal SAEs were reported in these two treatment arms, none of which was considered related to the study treatment. Two deaths occurred in the UMEC 62.5 lg ? ICS/ LABA group (one due to gastric ulcer hemorrhage with myocardial infarction and one to lymphoma). There were six deaths in Table 3 Lung function, rescue use and SGRQ endpoint comparisons (by subgroups) (47) 53 (15) 227 (45) 68 (14) 182 (44) 55 (13) 195 (48) 66 (16) Odds ratio (95% CI) 134 (43) 109 (33) 190 (40) 131 (29) 152 (37) 115 (28) 172 (45) 125 (33) A surprising finding of this pooled post hoc analysis was that the magnitude of improvements in lung function were remarkably consistent in all subgroups, as well as with those reported in previous trials investigating UMEC 62.5 lg as a monotherapy [12] [13] [14] . This suggests that symptomatic patients treated with combination ICS/LABA often have the potential for clinically important improvements in lung function [15] • ▲ ▲ ▲ ▲ ▲ ▲ ▲ ▲▲ ▲ ▲ ▲ ▲ chronic Obstructive Lung Disease, ICS inhaled corticosteroid, LABA long-acting beta 2 agonist, LS least squares, MCID minimal clinically important difference (defined as a C100 mL treatment difference), PBO placebo, UMEC umeclidinium versus tiotropium on moderate exacerbations in a small, 12-month study confounded by very high dropout rates. However, they were able to show a reduction in severe exacerbations with triple therapy [17] . In this post hoc analysis of over 1600 patients, despite the short study length, we found a statistically significant reduction in the risk of a first moderate/severe exacerbation when adding UMEC 62.5 lg to ICS/LABA therapy. This finding was consistent across subgroups, despite the low number of events reported. One other larger, but shorter (3 months) study of triple therapy versus tiotropium corroborates these findings [18] . As high dropout rates may confound many long-term exacerbation studies performed in high-risk patients [17, 19] , the approach of pooling data from short-term studies may provide an alternative insight on how best to examine exacerbations in higher-risk patients with COPD. However, it is important to recognize a key limitation of our findings: that they have been obtained as part of a post hoc analysis. Caution is also needed in generalizing the magnitude of the exacerbation benefits observed here, as experience of a previous exacerbation was not an inclusion criteria for the study, thereby potentially minimizing the level of events observed. ClinicalTrials.gov identifier: NCT02164513) study is currently ongoing and may answer some of these critical questions regarding COPD treatment [20] . Active pharmacovigilance evaluation of these treatments is also underway to further characterize their safety profiles.
The strengths of this post hoc analysis were that it included four studies with high completion and retention rates. The design of these double-blind, PBO-controlled studies was robust. Two replicate studies were performed for addition of UMEC to FP/SAL and to FF/VI, thus confirming efficacy and safety results. Although these post hoc analyses used data pooled from four studies of short duration, they provide new information about UMEC 62.5 lg added to ICS/ LABA. Additional studies could compare triple therapy to LAMA/LABA dual therapy, to ascertain the treatment benefits of ICS in the triple combination. Our analysis also focused only on the GOLD guidelines in place at the time of the study, dividing patients into subgroups based on the A-D classification, but lacked data in less symptomatic patients in groups A and C. As the GOLD guidelines are updated annually, future analyses may require further refinement. The current GOLD guidelines have limited information on phenotypes such as the asthma-COPD overlap syndrome [1] . In an attempt to address such limitations, other national guidelines for the treatment of patients with COPD have been developed, for example, in Spain [21] , Finland [22] and the Czech Republic [23] . Future studies could investigate which specific phenotypes, highlighted in these national guidelines [21] [22] [23] , would benefit from triple therapy with LAMA ? ICS/LABA. All data are presented as n (%) AE adverse event, ICS inhaled corticosteroid, ITT intent-to-treat, LABA long-acting beta 2 agonist, LRTI lower respiratory tract infection, PBO placebo, SAE serious adverse event, UMEC umeclidinium
